In a study using three groups (Pso, AD, controls), the levels of pro-inflammatory cytokines were assessed and, along with IL-17 and -23, common targets for current therapies in Pso as well asIL-31 resulted in elevated levels in the patients’ sera [42]. Here, IL17A is linked to Alzheimer disease.